JP2021531280A - 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 - Google Patents

神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 Download PDF

Info

Publication number
JP2021531280A
JP2021531280A JP2021502704A JP2021502704A JP2021531280A JP 2021531280 A JP2021531280 A JP 2021531280A JP 2021502704 A JP2021502704 A JP 2021502704A JP 2021502704 A JP2021502704 A JP 2021502704A JP 2021531280 A JP2021531280 A JP 2021531280A
Authority
JP
Japan
Prior art keywords
disease
protein
glial
marker
treg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021502704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021531280A5 (https=
JPWO2019190879A5 (https=
Inventor
フィリップ ジー． アシュトン−リッカルト，
Original Assignee
スミス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミス セラピューティクス インコーポレイテッド filed Critical スミス セラピューティクス インコーポレイテッド
Publication of JP2021531280A publication Critical patent/JP2021531280A/ja
Publication of JP2021531280A5 publication Critical patent/JP2021531280A5/ja
Publication of JPWO2019190879A5 publication Critical patent/JPWO2019190879A5/ja
Priority to JP2024063938A priority Critical patent/JP7697096B2/ja
Priority to JP2025097962A priority patent/JP2025123315A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021502704A 2018-03-27 2019-03-21 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療 Pending JP2021531280A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024063938A JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648684P 2018-03-27 2018-03-27
US62/648,684 2018-03-27
PCT/US2019/023395 WO2019190879A1 (en) 2018-03-27 2019-03-21 Car-treg-based therapies for treating neurodegenerative diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024063938A Division JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Publications (3)

Publication Number Publication Date
JP2021531280A true JP2021531280A (ja) 2021-11-18
JP2021531280A5 JP2021531280A5 (https=) 2022-03-24
JPWO2019190879A5 JPWO2019190879A5 (https=) 2022-03-24

Family

ID=68060734

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021502704A Pending JP2021531280A (ja) 2018-03-27 2019-03-21 神経変性疾患を処置するためのＣＡＲ−Ｔｒｅｇベースの治療
JP2024063938A Active JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A Pending JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024063938A Active JP7697096B2 (ja) 2018-03-27 2024-04-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP2025097962A Pending JP2025123315A (ja) 2018-03-27 2025-06-11 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Country Status (7)

Country Link
US (2) US12173030B2 (https=)
EP (1) EP3773629A4 (https=)
JP (3) JP2021531280A (https=)
KR (2) KR102892999B1 (https=)
CN (1) CN112867496B (https=)
AU (1) AU2019242381B2 (https=)
WO (1) WO2019190879A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024086870A (ja) * 2018-03-27 2024-06-28 エーゼットセラピーズ， インコーポレイテッド 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7821119B2 (ja) 2020-04-23 2026-02-26 エーゼットセラピーズ， インコーポレイテッド Ｈｌａクラスｉ ｍｈｃの細胞切除
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
EP4396216A1 (en) * 2021-09-03 2024-07-10 Sangamo Therapeutics, Inc. Mog-binding proteins and uses thereof
TW202321286A (zh) * 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
CN118272314A (zh) * 2024-04-15 2024-07-02 华中科技大学同济医学院附属同济医院 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
US20080027001A1 (en) 2006-07-07 2008-01-31 Andrew Wood Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
SG193023A1 (en) * 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
KR20140071277A (ko) 2011-05-19 2014-06-11 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
SG10202013095YA (en) * 2014-12-30 2021-02-25 Brigham & Womens Hospital Inc Methods to improve cell therapy
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
CN107708733B (zh) * 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
WO2017100428A1 (en) * 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
EP4321649B1 (en) * 2017-11-11 2025-08-20 Micromaterials LLC Gas delivery system for high pressure processing chamber
CN112867496B (zh) * 2018-03-27 2026-03-17 阿尔茨治疗方法公司 用于治疗神经退行性疾病的基于car-treg的疗法
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024086870A (ja) * 2018-03-27 2024-06-28 エーゼットセラピーズ， インコーポレイテッド 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
JP7697096B2 (ja) 2018-03-27 2025-06-23 エーゼットセラピーズ， インコーポレイテッド 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療

Also Published As

Publication number Publication date
KR20210135921A (ko) 2021-11-16
US20250129158A1 (en) 2025-04-24
CA3095298A1 (en) 2019-10-03
JP2025123315A (ja) 2025-08-22
AU2019242381A1 (en) 2020-11-19
CN112867496B (zh) 2026-03-17
EP3773629A4 (en) 2022-01-19
WO2019190879A1 (en) 2019-10-03
KR102892999B1 (ko) 2025-11-28
CN112867496A (zh) 2021-05-28
AU2019242381B2 (en) 2025-04-24
KR20250174989A (ko) 2025-12-15
EP3773629A1 (en) 2021-02-17
US12173030B2 (en) 2024-12-24
JP2024086870A (ja) 2024-06-28
JP7697096B2 (ja) 2025-06-23
US20210023137A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
JP7697096B2 (ja) 神経変性疾患を処置するためのＣＡＲ－Ｔｒｅｇベースの治療
Zhang et al. Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke
Manjunatha et al. Multiple sclerosis: therapeutic strategies on the horizon
JP2024012513A (ja) フルオレセイン結合エーテルリン脂質（ｆｌ－ｐｌｅ）で標識された腫瘍に対して最適なｔ細胞機能を示すフルオレセイン特異的ｃａｒ
JP2019534898A (ja) 中枢神経系の疾患および障害を処置するための組成物および方法
Rinaldi et al. Therapeutic effect of bifidobacterium administration on experimental autoimmune myasthenia gravis in Lewis rats
TWI717848B (zh) 抗體於治療神經退化性疾病的用途
JP2023021131A (ja) 免疫を調節するペプチド、ポリペプチド又は細胞を作製する方法
US20230210899A1 (en) CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
US11103486B2 (en) Treatment of autoimmune disorders and infections using antagonists of SGK1 activity
Li et al. Anti‐Inflammatory Macrophage‐Derived Exosomes Modified With Self‐Antigen Peptides for Treatment of Experimental Autoimmune Encephalomyelitis
KR20070007291A (ko) 면역 반응을 유도하거나 조절하는 방법
CA3095298C (en) Car-treg-based therapies for treating neurodegenerative diseases
HK40122801A (zh) 用於治疗神经变性疾病的靶向髓鞘少突胶质细胞糖蛋白(mog)的基於car-treg的疗法
HK40099093A (zh) 用於治疗神经变性疾病的靶向髓鞘少突胶质细胞糖蛋白(mog)的基於car-treg的疗法
US20190328781A1 (en) Manufacturing methods for cell-based therapeutic compositions
Meng et al. Pediatric Anti-Glyr Antibody-Associated Progressive Encephalomyelitis with Rigidity and Myoclonus-A Case Report and Literature Review
WO2025250591A1 (en) Abc and gate car-t cell therapy for autoimmune disease
WO2025253079A1 (fr) Anticorps monoclonal d'isotype igm anti-hla-dr potentialisant l'activite d'anticorps d'isotype igg1 ou igm anti-cd20

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220315

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230329

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231211